NT-125 is discontinued, while two key Datroway readouts are delayed.

A Pfizer cast-off could become the company's first marketed drug.

Meanwhile, investors await key clinical data.

But BeOne canned its alcestobart deal in May.

Tiragolumab failed the Skyscraper-14 and 03 studies, Roche quietly reveals.

Biopharma's interest in CDH17 and CDH6 continues, courtesy of Lepu and Qilu.